Morgan Stanley Buys 66,429 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)


Share on StockTwits

Morgan Stanley grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 31.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 277,323 shares of the specialty pharmaceutical company’s stock after purchasing an additional 66,429 shares during the period. Morgan Stanley’s holdings in Jazz Pharmaceuticals were worth $45,771,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the company. CWM LLC grew its stake in shares of Jazz Pharmaceuticals by 41.0% in the 4th quarter. CWM LLC now owns 258 shares of the specialty pharmaceutical company’s stock valued at $43,000 after purchasing an additional 75 shares during the period. Captrust Financial Advisors grew its position in Jazz Pharmaceuticals by 4.1% during the 4th quarter. Captrust Financial Advisors now owns 2,820 shares of the specialty pharmaceutical company’s stock worth $465,000 after acquiring an additional 110 shares during the last quarter. Kendall Capital Management grew its position in Jazz Pharmaceuticals by 1.7% during the 4th quarter. Kendall Capital Management now owns 7,275 shares of the specialty pharmaceutical company’s stock worth $1,201,000 after acquiring an additional 125 shares during the last quarter. Bessemer Group Inc. grew its position in Jazz Pharmaceuticals by 9.1% during the 4th quarter. Bessemer Group Inc. now owns 1,912 shares of the specialty pharmaceutical company’s stock worth $316,000 after acquiring an additional 159 shares during the last quarter. Finally, NEXT Financial Group Inc bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $32,000. Institutional investors own 95.67% of the company’s stock.

A number of equities research analysts recently commented on JAZZ shares. SVB Leerink restated an “outperform” rating on shares of Jazz Pharmaceuticals in a research report on Monday, March 15th. Jefferies Financial Group increased their price target on Jazz Pharmaceuticals from $209.00 to $214.00 and gave the stock a “buy” rating in a research report on Wednesday, February 24th. Morgan Stanley increased their price target on Jazz Pharmaceuticals from $162.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 1st. Zacks Investment Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating and set a $181.00 price objective on the stock in a report on Wednesday, March 17th. Finally, HC Wainwright upped their price objective on Jazz Pharmaceuticals from $195.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, February 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have issued a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $185.61.

Shares of Jazz Pharmaceuticals stock opened at $161.93 on Thursday. The company has a market capitalization of $9.12 billion, a PE ratio of 51.08, a PEG ratio of 4.64 and a beta of 1.08. Jazz Pharmaceuticals plc has a 12 month low of $101.81 and a 12 month high of $178.64. The company has a current ratio of 3.98, a quick ratio of 3.84 and a debt-to-equity ratio of 0.55. The stock’s fifty day simple moving average is $166.13 and its 200 day simple moving average is $156.03.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 23rd. The specialty pharmaceutical company reported $4.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.42. The business had revenue of $665.52 million for the quarter, compared to the consensus estimate of $639.83 million. Jazz Pharmaceuticals had a return on equity of 20.16% and a net margin of 7.86%. The firm’s revenue was up 14.4% compared to the same quarter last year. During the same quarter last year, the business posted $4.42 EPS. Analysts predict that Jazz Pharmaceuticals plc will post 10.83 EPS for the current fiscal year.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $164.96, for a total transaction of $247,440.00. Following the completion of the transaction, the chief executive officer now owns 323,341 shares in the company, valued at approximately $53,338,331.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.60% of the stock is currently owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca.

Read More: How to execute a trade ex-dividend strategy?

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.